Recruiting
Phase 2

Stereotactic Ablative Radiotherapy for Oligo-Progressive Disease REfractory to Systemic Therapy in Metastatic Cancer

Sponsor:

Centre hospitalier de l'Université de Montréal (CHUM)

Code:

NCT04989725

Conditions

Head and Neck Cancer

Metastatic Cancer

Oligoprogressive

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Standard arm

Experimental arm

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information